Drug Profile
GKM 002
Alternative Names: GKM-002Latest Information Update: 07 Dec 2018
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 07 Dec 2018 No development reported - Phase-II for Type 2 diabetes mellitus in India (PO)
- 29 Nov 2011 Preclinical trials in Type-2 diabetes mellitus in India (PO)